Tempest Therapeutics, Inc. - Common Stock (TPST)

Competitors to Tempest Therapeutics, Inc. - Common Stock (TPST)

Agenus Inc. 

Agenus Inc. focuses on immuno-oncology therapies, much like Tempest Therapeutics, which also develops treatments targeting tumor microenvironments. The two companies both seek to enhance immune response against cancer cells; however, Agenus has a more established pipeline with multiple clinical trials underway. This gives Agenus a competitive advantage in that it has accumulated more data on efficacy and safety, which may lead to a faster path to market for its therapies.

Blueprint Medicines Corporation 

Blueprint Medicines targets genomic drivers of cancer with a focus on precision medicine and targeted therapies. While Tempest Therapeutics is developing treatments aimed at the broader tumor environment, Blueprint's specific focus on genetic mutations may appeal to a different segment of the oncology market. Blueprint's established relationships with major pharmaceutical companies and a robust clinical development pipeline provide them with a significant advantage in terms of resources and reach.

Iovance Biotherapeutics, Inc. 

Iovance Biotherapeutics is focused on introducing tumor-infiltrating lymphocyte (TIL) therapies for solid tumors, providing a specific niche that may intersect with Tempest Therapeutics' offerings. While both companies aim to utilize immune mechanisms against cancer, Iovance's focus on expanding TIL technology offers a unique framework that may appeal to investors looking for targeted approaches to solid tumors. Iovance is currently ahead with a product nearing approval, which places it in a favorable position compared to Tempest.

OncoSec Medical Incorporated

OncoSec Medical is also in the field of immunotherapy, focusing specifically on intratumoral delivery of therapeutic DNA plasmids intended to enhance the immune response against tumors. While both OncoSec and Tempest aim to leverage the immune system in fighting cancer, OncoSec has a unique delivery mechanism that sets its approach apart. Additionally, OncoSec has progressed further in clinical trials, giving it immediate competitive advantages regarding data and investor confidence.